Details of the Drug

General Information of Drug (ID: DMXVRI0)

Drug Name
Beclanorsen
Synonyms SPC-2004; SPC-2993; SPC-2996; Anti-Bcl-2 (LNA antisense therapy), Santaris
Indication
Disease Entry ICD 11 Status REF
leukaemia 2A60-2B33 Phase 1/2 [1]
Drug Type
Antisense drug
Sequence
CUCCCAACGTGCGCCA
Cross-matching ID
UNII
ZV9069GJO5
DrugBank ID
DB05606
TTD ID
D00GAM

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
BCL-2 messenger RNA (BCL2 mRNA) TTFOUV4 BCL2_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease leukaemia
ICD Disease Classification 2A60-2B33
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
BCL-2 messenger RNA (BCL2 mRNA) DTT BCL2 8.27E-03 0.06 0.13
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT00285103) SPC2996 in Chronic Lymphocytic Leukaemia. U.S. National Institutes of Health.
2 Combination of novel imidazopyridazine mps-1 kinase inhibitors and bcl-2 family protein inhibitors. ACS Med Chem Lett. 2014 Jul 30;6(1):7-8.